Compare BMHL & ALDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BMHL | ALDX |
|---|---|---|
| Founded | 2016 | 2004 |
| Country | Hong Kong | United States |
| Employees | 9 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 100.8M | 101.1M |
| IPO Year | N/A | 2014 |
| Metric | BMHL | ALDX |
|---|---|---|
| Price | $3.94 | $1.72 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $5.50 |
| AVG Volume (30 Days) | 2.4K | ★ 1.1M |
| Earning Date | 06-13-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 40.43 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $66.66 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.72 | $1.07 |
| 52 Week High | $4.48 | $6.18 |
| Indicator | BMHL | ALDX |
|---|---|---|
| Relative Strength Index (RSI) | 64.06 | 42.12 |
| Support Level | $3.25 | $1.48 |
| Resistance Level | $4.20 | $1.89 |
| Average True Range (ATR) | 0.15 | 0.10 |
| MACD | 0.05 | 0.08 |
| Stochastic Oscillator | 92.31 | 62.82 |
Bluemount Holdings Ltd through its operating subsidiaries, it is a Hong Kong-based consulting and advisory and financial services provider, as well as trader of commodities such as luxury timepieces. The financial services includes underwriting and placing services, securities dealing and brokerage services, and asset management services. It provides comprehensive consulting and advisory services on business development strategies to its diverse clientele. Generally, the company provides consulting and advisory business for the following segments: Corporate Finance; and Strategic Communications.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma, and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.